China’s biopharmaceutical landscape is experiencing a remarkable transformation as it kicks off 2026 with unprecedented growth in cross-border out-licensing activities. This surge indicates not only the increasing confidence in domestic innovative drug development but also China’s evolving role in the global biotechnology arena.
Record Out-Licensing Activity
Recent statistics from the National Medical Products Administration reveal that out-licensing agreements for innovative drugs in China surpassed $60 billion in the first quarter of 2026. This impressive figure accounts for nearly half of the total $135.7 billion recorded throughout 2025. The data underscores the strength of the biopharmaceutical sector and its capacity to engage globally.
During the 2026 Zhongguancun Forum, a regulatory official highlighted the sector’s “historic breakthroughs,” marking a robust beginning for the 15th Five-Year Plan period, which spans from 2026 to 2030. This optimistic outlook is further bolstered by the approval of ten innovative drugs, eight of which were developed domestically.
Growing International Confidence
The increase in out-licensing deals, often referred to as business development (BD), illustrates the growing international trust in China’s research capabilities. Under these agreements, Chinese pharmaceutical firms grant exclusive rights to drug candidates or technology platforms to global partners, receiving upfront payments, milestone fees, and future sales royalties in return.
A notable example from this quarter is CSPC Pharmaceutical Group Ltd, based in Hebei province. In January, the company entered into a multi-project collaboration with AstraZeneca to develop long-acting peptide drugs utilizing CSPC’s innovative sustained-release drug delivery platform and AI-driven peptide discovery technology. AstraZeneca’s CEO, Pascal Soriot, remarked that such partnerships reflect the rapid ascent of China’s biotech sector.
Evolving Deal Structures
The trend of increased collaboration is further evidenced by the sheer volume of deals. According to industry insights from PharmCube, Chinese drugmakers engaged in over 150 out-licensing agreements in 2025, with total deal values more than doubling compared to the previous year. Analysts from China Galaxy Securities note a shift in transaction structures from single-asset licensing to broader platform partnerships, driven by global pharmaceutical companies’ desire to tap into China’s competitive discovery landscape.
Financial Performance and Policy Support
The momentum in the biopharmaceutical industry is also mirrored in corporate earnings. Financial data indicates that over 70 percent of Chinese biopharmaceutical companies reporting their 2025 results achieved profitability, with many innovators experiencing triple-digit earnings growth. This suggests that income from out-licensing and the commercialization of drugs are beginning to compensate for previous years of substantial research expenditure.
Supportive government policies further enhance the sector’s development trajectory. For the first time, the 2026 Government Work Report recognized biopharmaceuticals as a burgeoning pillar industry, placing it alongside sectors like integrated circuits and aerospace. Upcoming regulatory reforms, including a revised drug administration law effective May 15, will introduce measures such as six-year regulatory data protection and extended market exclusivity for rare-disease drugs, enhancing the attractiveness of China for global drug development ventures.
Challenges Ahead
Despite these positive trends, industry leaders caution that challenges persist. Sun Piaoyang, chairman of Jiangsu Hengrui Pharmaceuticals, pointed out that competition surrounding popular drug targets is intensifying, and the limitations of original discovery capabilities could hinder long-term innovation. Moreover, Chinese companies still encounter difficulties in conducting large-scale global clinical trials and establishing commercialization frameworks abroad.
A Structural Shift in the Sector
Nevertheless, the trajectory for China’s pharmaceutical sector is one of significant evolution. Analysts contend that as domestic scientific capabilities strengthen and global partnerships expand, the industry is undergoing a structural shift. This synergy of homegrown innovation and international collaboration positions China to play a more prominent role in global drug innovation and health governance.
In conclusion, the biopharmaceutical sector in China is on the verge of a new chapter, characterized by unprecedented growth and collaboration. As the landscape continues to evolve, the combination of innovative capabilities and strategic partnerships is likely to propel China into a leading position in the global biopharmaceutical market.
- Key Takeaways:
- Record out-licensing deals highlight China’s growing influence in global biotechnology.
- Collaborative partnerships with multinational companies are becoming more common.
- Financial performance indicates a shift towards profitability in the sector.
- Government support and regulatory reforms are enhancing the business environment.
- Challenges remain, particularly in original discovery and global trial execution.
Read more → www.chinadaily.com.cn